Jiangsu Zhonghui Yuantong Bio-technology

Jiangsu Zhonghui Yuantong Bio-technology is a Chinese biotechnology company specializing in the research, development, and manufacturing of innovative human vaccines. Headquartered in Taizhou's China Medical City, the company leverages advanced technology platforms, including cell-based vaccine production and novel adjuvant systems, to address significant public health challenges. Its flagship product, a quadrivalent influenza vaccine (split virion), has received regulatory approval and is commercially available in China. The company is also advancing a robust pipeline of next-generation candidates, including a cell-based quadrivalent flu vaccine and a human diploid cell rabies vaccine, both in late-stage clinical development. Supported by prominent investors such as Hillhouse Capital and Sequoia China, Zhonghui Yuantong operates state-of-the-art GMP manufacturing facilities. The company aims to provide high-quality, affordable immunization solutions for both domestic and international markets.